Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering - Compass Therapeutics (NASDAQ:CMPX)

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering - Compass Therapeutics (NASDAQ:CMPX)

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ("Compass") (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6…

Compass Therapeutics sells $120M in stock; RemeGen to seek China approval

Plus, news about Generation Bio, Response Pharmaceuticals, Jocasta Neuroscience, Oric, ALX Oncology, Fate Therapeutics, X4 Pharmaceuticals and Armata: 🧭 Compass Therapeutics sells $120M in shares: The Boston-based biotech plans to

Cancer Drug Developer Compass Therapeutics Secures $120M to Advance Commercial Plans

Oncology biotech prices 40M shares at $3.00, including pre-funded warrants. Funds target commercial readiness and clinical development pipeline. See investment details.